SCHEMBL10256809

SCHEMBL10256809

Cc1nc(C(F)(F)F)c(C(=O)NC2CCCc3cc(C(=O)NO)ccc32)s1

nearest known ligand 0.54

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.54
CNR2 P34972 1/20 0.54
LMNA P02545 2/20 0.45
PDE2A O00408 2/20 0.43
TAS1R3 Q7RTX0 6/20 0.43
TAS1R1 Q7RTX1 6/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
TAS1R2 Q8TE23 4/20 0.42
HSD11B1 P28845 1/20 0.41
BDKRB1 P46663 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10246861 0.88 CNR1 (0.70) CNR1CNR2LMNATAS1R3TAS1R1
SCHEMBL3395117 0.84 CNR1 (0.75) CNR1CNR2LMNATAS1R3TAS1R1
SCHEMBL6520141 0.84 CNR1 (0.75) CNR1CNR2LMNATAS1R3TAS1R1
SCHEMBL10252477 0.79 DHODH (0.54) LMNAPDE2ATAS1R3TAS1R1KMT2A
SCHEMBL10258791 0.77 TAS1R3 (0.52) LMNAPDE2ATAS1R3TAS1R1KMT2A
SCHEMBL10246859 0.77 LMNA (0.55) LMNAPDE2ATAS1R3TAS1R1KMT2A
SCHEMBL10246997 0.77 LMNA (0.62) LMNATAS1R3TAS1R1KMT2AMEN1
SCHEMBL10252923 0.76 HDAC8 (0.57) LMNAPDE2ATAS1R3TAS1R1KMT2A
SCHEMBL10246865 0.75 LMNA (0.54) LMNATAS1R3TAS1R1KMT2AMEN1
SCHEMBL10247155 0.75 LMNA (0.77) LMNATAS1R3TAS1R1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
WO-2012012322-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-01-26 WO disclosed
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACUTICALS, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 CNR1 2818/4885CNR2 1904/4885LMNA 1529/4885
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, H1-3 CNR1 1527/4885CNR2 887/4885LMNA 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.